342 related articles for article (PubMed ID: 18479249)
1. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
[TBL] [Abstract][Full Text] [Related]
2. Effects of N-acetylcysteine administration in hepatic microcirculation of rats with biliary cirrhosis.
Yang YY; Lee KC; Huang YT; Wang YW; Hou MC; Lee FY; Lin HC; Lee SD
J Hepatol; 2008 Jul; 49(1):25-33. PubMed ID: 18490076
[TBL] [Abstract][Full Text] [Related]
3. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.
Lee KC; Yang YY; Huang YT; Lee FY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2010 Apr; 119(1):45-55. PubMed ID: 20132096
[TBL] [Abstract][Full Text] [Related]
4. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension.
Biecker E; Trebicka J; Kang A; Hennenberg M; Sauerbruch T; Heller J
Liver Int; 2008 Mar; 28(3):331-8. PubMed ID: 18290775
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide decreases intrahepatic resistance in cirrhotic rats.
Yang YY; Huang YT; Lin HC; Lee FY; Lee KC; Chau GY; Loong CC; Lai CR; Lee SD
Biochem Biophys Res Commun; 2009 Mar; 380(3):666-72. PubMed ID: 19285019
[TBL] [Abstract][Full Text] [Related]
6. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
7. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
8. Amiloride reduces portal hypertension in rat liver cirrhosis.
Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
[TBL] [Abstract][Full Text] [Related]
9. Lipoic acid prevents development of the hyperdynamic circulation in anesthetized rats with biliary cirrhosis.
Marley R; Holt S; Fernando B; Harry D; Anand R; Goodier D; Davies S; Moore K
Hepatology; 1999 May; 29(5):1358-63. PubMed ID: 10216116
[TBL] [Abstract][Full Text] [Related]
10. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
Lin HC; Yang YY; Tsai TH; Huang CM; Huang YT; Lee FY; Liu TT; Lee SD
J Hepatol; 2011 Jun; 54(6):1145-53. PubMed ID: 21145843
[TBL] [Abstract][Full Text] [Related]
11. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.
Zhou Q; Hennenberg M; Trebicka J; Jochem K; Leifeld L; Biecker E; Sauerbruch T; Heller J
Gut; 2006 Sep; 55(9):1296-305. PubMed ID: 16492715
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
[TBL] [Abstract][Full Text] [Related]
13. Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition.
Huang HC; Wang SS; Lee FY; Chang CC; Chang FY; Lin HC; Hou MC; Lee SD
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e265-9. PubMed ID: 17764528
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
15. Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis.
Yang YY; Huang YT; Tsai TH; Hou MC; Lee FY; Lee SD; Lin HC
Clin Sci (Lond); 2012 Dec; 123(12):669-80. PubMed ID: 22734967
[TBL] [Abstract][Full Text] [Related]
16. The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis.
Albillos A; Nieto M; Ubeda M; Muñoz L; Fraile B; Reyes E; Lledó L; Blanco I; Pastor O; Salas C; Lario M; Monserrat J; Bataller R; Alvarez-Mon M
Gut; 2010 Jul; 59(7):943-52. PubMed ID: 20442198
[TBL] [Abstract][Full Text] [Related]
17. Herb medicine Yin-Chen-Hao-Tang ameliorates hepatic fibrosis in bile duct ligation rats.
Lee TY; Chang HH; Chen JH; Hsueh ML; Kuo JJ
J Ethnopharmacol; 2007 Jan; 109(2):318-24. PubMed ID: 16989967
[TBL] [Abstract][Full Text] [Related]
18. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
Berzigotti A; Bellot P; De Gottardi A; Garcia-Pagan JC; Gagnon C; Spénard J; Bosch J
Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806
[TBL] [Abstract][Full Text] [Related]
19. [Serum hyaluronic acid level: correlation with quantitative measurement of hepatic fibrosis in a cirrhotic rat model].
Kim MY; Baik SK; Jang YO; Suk KT; Kim JW; Kim HS; Cho MY; Choi SJ; Um SH; Han KH
Korean J Hepatol; 2008 Jun; 14(2):159-67. PubMed ID: 18617763
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
